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Abstract 21 
Objectives. The aim was to investigate an unusual outbreak of 5 patients with in total 8 episodes of a 22 
Clostridium difficile infection (CDI) on a gastro intestinal surgical ward of a Dutch tertiary care 23 
university affiliated hospital.  24 
Methods. Clinical case investigations and laboratory analyses were performed. Laboratory analyses 25 
included PCR ribotyping, MLVA typing, toxinotyping, antimicrobial susceptibility testing and whole 26 
genome sequencing.   27 
Results. The outbreak was associated with recurrent and severe disease in 2 out of 5 patients.  All 28 
episodes were due to a unique ribotype that was not recognized in the collection of an international 29 
network of reference laboratories and was assigned PCR ribotype 826. PCR ribotype 826 is a toxin A, 30 
toxin B and binary toxin positive ribotype which according to molecular typing belongs to clade 5 31 
and resembles the so called “hypervirulent “ ribotype 078. The presence of a clonal outbreak was 32 
confirmed by whole genome sequencing, yet the source of this newly identified ribotype remained 33 
unclear. 34 
Conclusion. This newly identified C. difficile PCR ribotype 826 is part of clade 5 and might as well 35 
have increased virulence. The recognition of this outbreak highlights the need of ongoing CDI 36 
surveillance to monitor new circulating ribotypes with assumed increased virulence. 37 
 38 
 39 
 40 
 41 
 42 
 43 
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Introduction 44 
We identified an outbreak of eight episodes of CDI in five patients within a 4-month period (1 45 
December 2015-31 March 2016). The outbreak occurred on a gastro-intestinal surgical ward of a 46 
Dutch tertiary care hospital. In this case series, we describe the clinical characteristics of affected 47 
patients and microbiological investigations that were performed on the identified strain.   48 
 49 
Methods 50 
The case series was conducted at a gastro-intestinal surgical ward of the Erasmus University Medical 51 
Center in Rotterdam, the Netherlands. The Erasmus MC participates in the national sentinel CDI 52 
surveillance program and therefore sends all samples from hospitalized CDI patients to the national 53 
Reference Laboratory for PCR ribotyping (1, 2). In case of an outbreak (defined as >2 isolates of the 54 
same type detected less than 7 days apart in one hospital either with onset of symptoms on the 55 
same ward, or accompanied by an increased CDI monthly incidence within the hospital (3)) 56 
additional analyses can be performed by the Reference Laboratory. These include multiple-locus 57 
variable-number tandem-repeat analysis (4) , PCRs for toxin genes (5), PCRs for clade specific makers 58 
(6), antimicrobial susceptibility screening tests (E-test) and whole genome sequencing (7). 59 
Patient information and medical history from all CDI cases during this outbreak were collected from 60 
the electronical medical records.  Defined daily doses for all antibiotics used up to three months 61 
before development of CDI and Charlson co-morbidity scores were calculated. (8). CDI was classified 62 
as severe if one or more of the following conditions were present (attributable to CDI): fever (equal 63 
or above 38.5°C), rigors, hemodynamic instability, ileus, peritonitis, mental status changes, 64 
admission to ICU, end organ failure, leukocytosis (>15 x 10
9
), leukopenia (<2 x 10
9
), 65 
hypoalbuminemia (<30g/L), >1.5-fold increase in creatinine level above baseline, serum lactate 66 
>2.2mmol/L, pseudomembranous colitis, colonic wall thickening, pericolonic fat stranding or ascites. 67 
All other cases were classified as mild CDI. (9, 10).  68 
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Written approval to conduct the case series was received from the medical ethics research 69 
committee of the Erasmus MC Rotterdam, the Netherlands (MEC-2015-306).  70 
 71 
Results 72 
The CDI incidence rate on the gastro-intestinal surgical ward was 3.3 per 10,000 patient days (July 73 
2009-November 2015) and increased to 19.8 per 10,000 patient days (December 2015-March 2016). 74 
In total, 6 patients with CDI were diagnosed of which 5 had the same PCR ribotype.   75 
The index case A of this outbreak was an 83-year old male patient who underwent a 76 
pancreaticoduodenectomy because of a carcinoma of the common bile duct one month earlier. In 77 
December 2015, during a readmission because of infected ascites, he developed diarrheal symptoms 78 
and was diagnosed with hospital-acquired CDI. Within one week after the start of his symptoms, two 79 
other patients (B and C) on the same ward were diagnosed with hospital-acquired CDI. All three 80 
patients were treated with a 7-11 day oral course of metronidazole and discharged. 81 
 82 
In January 2016, a fourth hospital-acquired CDI case (D) on the ward was noticed. In February 2016, 83 
case A was readmitted because of a CDI recurrence and a fifth case (E) was reported. Case A was 84 
readmitted once more due to a second recurrence in February and case D was also diagnosed with a 85 
CDI recurrence in March. In total, 4 out of 8 CDI episodes (in 2 patients) were classified as severe 86 
CDI. None of the patients were admitted to the ICU due to CDI, and no CDI-related mortality (within 87 
30 days) occurred.  All patients had used antibiotics before acquiring CDI and total defined daily 88 
doses of antibiotics used before onset of CDI ranged from 21 to 63 (median 26.9). Four out of 5 89 
patients had used proton pump inhibitors before the CDI diagnosis. The median Charlson co-90 
morbidity score was 2, ranging from 0 to 8.  91 
In accordance with local guidelines, all patients suspected of or having CDI were placed in a single 92 
room and were not allowed to use shared sanitation. Medical personnel wore protective disposable 93 
gowns and gloves when entering the room and handwashing with soap and water was endorsed. 94 
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Isolation precautions were discontinued 48hours after resolution of diarrheal symptoms. In reaction 95 
to this CDI outbreak, additional infection prevention measures were implemented on the ward 96 
during certain time periods (see Figure 1).These additional infection prevention measures included 97 
cleaning and disinfection using 1000ppm chlorine of the following items: automatic bedpan washer 98 
(daily), toilet chairs (after each use), utility room and sanitation (daily or twice daily) and all patients 99 
rooms of half the department (once, after recognition of the fifth case). Additionally, the metal 100 
bedpans were replaced by cardboard single use bedpans. Moreover, after the fifth case was 101 
diagnosed, 56 environmental swabs were taken on 2 different sampling days: February 19
th
 and 102 
February 24
th
. Samples were taken from: sink, water tap, grip of cabinet, alarm system, dustbin, 103 
chairs/tables and bed curtains of a room that had been occupied by a CDI patient (before final 104 
cleaning); the same items in a clean room (after cleaning and disinfection with 1000pppm); and 105 
toilet, shower chair, sink, shower curtain, sack of laundry and towel dispenser of a shared bathroom 106 
(after cleaning and disinfection). Environmental swabs were inoculated in C. difficile enrichment 107 
modified broth (Clostridium difficile enrichment broth, Mediaproducts BV, Groningen, The 108 
Netherlands) for 1 week and subcultured on CLO plates (Clostridium difficile agar, Biomerieux, Marcy 109 
l’Etoile, France). No antibiotic restriction policy was implemented during this outbreak. 110 
 111 
Stool samples of all 5 patients tested positive for toxin B and binary toxin genes in the Xpert C. 112 
difficile; however, the TcdC∆117 deletion specific for ribotype 027 was not identified. Investigations 113 
at the Reference Laboratory demonstrated the presence of TcdA, and confirmed the presence TcdB 114 
and the binary toxin genes. In addition, a 39-bp deletion in TcdC was detected.  115 
All 5 isolates and one isolate obtained from an environmental culture (taken from the sack of 116 
laundry in the shared bathroom after cleaning and disinfection) displayed the same PCR ribotyping 117 
profile. The profile was not recognized in the Dutch Reference Library (which is able to recognize 221 118 
different PCR ribotypes) but resembled the profile of ribotypes 078, 126 and 066 most (all belonging 119 
to clade 5) (Figure 2a). A dataset of sized fragments obtained by capillary gel-based electrophoresis 120 
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PCR ribotyping (2) was sent as FSA-file to international C. difficile reference laboratories (including 121 
the Leeds collection encompassing more than 800 PCR ribotypes , the WEBRIBO system, the CDC 122 
database and databases from  Sweden, Portugal, Belgium, and Canada), but no match was found. 123 
The new strain was assigned as ribotype 826 by the Leeds Ribotyping reference network. PCR 124 
analysis of a clade 5 specific DNA marker (6) revealed that all ribotype 826 isolates were positive for 125 
the marker, confirming that ribotype 826 is part of clade 5.  126 
According to Clinical and Laboratory Standards Institute (CLSI) breakpoints, all isolates were 127 
susceptible for erythromycin (MIC<2), clindamycin (MIC<2), metronidazole (MIC=<2) and 128 
vancomycin (MIC<2), but resistant to ciprofloxacin (MIC>32) and moxifloxacin (MIC>32)(11).  129 
The isolates were 100% identical with 0 summed tandem-repeat differences (STRD), thereby 130 
confirming a clonal complex according to MLVA.  131 
In addition, whole genome sequencing was performed (Figure 2b). To provide phylogenetic context, 132 
reference strains 078, 126/078, 045, 033 and 066 and 4 patient samples from confirmed 078 cases 133 
were included. In total, 1678 SNPs were identified within this sample selection which is the expected 134 
variation between different ribotypes of one clade. Within the outbreak isolates, only 2 SNPs were 135 
identified (there was 1 SNP difference  between the isolate from the recurrence in case A compared 136 
to the initial case A isolate and 1 SNP difference between the case D /case E isolates and the initial 137 
case A isolate). Clonality of these cluster isolates was thus confirmed by whole genome sequencing 138 
as the commonly used cut-off for classifying isolates as clonal is 0-2 SNPs (7). 139 
 140 
Discussion 141 
The occurrence of this CDI outbreak was uncommon as it occurred on a ward where transmission of 142 
C. difficile was rare, as proven by sentinel CDI surveillance. Also, two out of five patients had 143 
recurrent disease and were severely affected. Cases were due to a newly identified ribotype 826. 144 
Additional investigations showed that ribotype 826 belongs to clade 5 with a characteristic clade 5 145 
specific DNA marker and a 39bp deletion in TcdC. Whole genome sequencing revealed that ribotype 146 
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826 resembles the ribotype 078 quite well.  CDI cases due to clade 5 ribotypes have been reported 147 
to be associated with the highest 14-day mortality (12). We therefore assume that this new ribotype 148 
also has increased virulence, explaining the occurrence of this outbreak.  149 
 150 
Whole genome sequencing results demonstrated clonality thereby confirming transmission, but still 151 
unanswered questions are what the source of this ribotype was and how transmission occurred. The 152 
index patient could have introduced this ribotype into the ward, although no unusual profession, 153 
recent travel or other remarkable expositions were reported. Alternatively, an undetected 154 
asymptomatic carrier might have introduced the ribotype and spread it to other patients. 155 
Transmission could have occurred via shared items as contamination was demonstrated in one of 156 
the environmental cultures, but unfortunately environmental swabs were only taken after the last 157 
patient was detected. The outbreak ceased with the implementation of additional infection 158 
prevention measures, suggesting that these cleaning and disinfection measures were effective, 159 
probably together with a raised awareness among the healthcare workers. Since most PCR ribotypes 160 
of clade 5 are also found in animals, it is tempting to speculate that the newly recognised ribotype 161 
826 derives from animals. The lack of this PCR ribotype in the databases of human collections 162 
supports this hypothesis. Unfortunately, reference laboratories for animal associated C. difficile 163 
infections are not available that could be used to match our isolates. To the best of our knowledge, 164 
no additional 826 isolates have been detected since this outbreak.  165 
 166 
This outbreak indicates that new C. difficile ribotypes with increased virulence still emerge, at 167 
unexpected locations and without a clear source. Given the increased virulence and still unknown 168 
source of this newly identified ribotype, ongoing CDI surveillance remains essential and other 169 
institutions should now be aware of ribotype 826.  170 
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Figure legends. 243 
Figure 1. Epidemic curve of the 5 case patients infected with C. difficile caused by PCR ribotype 826. 244 
Green = outbreak non-ICU ward, Orange= other non-ICU ward, Blue= ICU, Dark green = diarrhoeal 245 
episode, White += positive culture for C. difficile and mild C. difficile infection, White ++= positive 246 
culture for C. difficile and severe C. difficile infection, Black + = Positive C. difficile culture without 247 
diarrhoea, White ─ = NegaUve culture for C. difficile. Abbreviations: C&D= cleaning and disinfection, 248 
ICU= intensive care unit, OMT= outbreak management team 249 
 250 
 251 
 252 
Figure 2a. PCR ribotyping patterns for ribotype 066, 078, 126 and 826.The upper row indicates the 253 
fragment sizes. 254 
Figure 2b. Phylogenetic tree of ribotype 826 outbreak isolates and related ribotypes. 078; reference 255 
ribotype 078 strain; 066 reference ribotype 066 strain; 045; reference ribotype 045 strain; 126078 256 
reference ribotype 126/078 strain; 7005405_078/10015222_078, 8051728_078, 6072310_078; 257 
clinical patient CDI samples with confirmed ribotype 078 . 4_826; sample from case A (recurrent 258 
episode); 3_826; sample from case A (initial episode); 6_826; sample from case C; 1_826; sample 259 
from case D (recurrent episode); 2_826; sample from case D (initial episode); 8_826; sample from 260 
case D (initial episode, repeat sample), 5_826; sample from case E. The isolate from case B could not 261 
be sequenced.   262 
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3/12 contact-isolation, single room
Case B  +
3/12 contact-droplet isolation, single room
Case C  +
7/12 contact isolation, single room
Case D
Case E
3/12 First allert 8/12 all strains produced binary toxin (GeneXpert)
of patients with diarrheal complaints Additional measures installed: 
 - Daily C&D of the automatic bedpan washer using 1000ppm chlorine
 - C&D of toilet chairs (after each use) using 1000ppm chlorine
 - Daily C&D of utility room and sanitation using 1000ppm chlorine
 - Use of only cardboard single use bedpans in toilet chairs
23/12 Additonal measures were discontinued
Case A  ++  ++
Case B
Case C
Case D  ++  ++  +  -  -  ++  ++
1/2 contact isolation installed
Case E  -  +  -
18/2 contact isolation installed
17/2 case D identified with same 'unknown' ribotype as case A-C 18/2 case E identified, OMT 25/4 Additional measures were discontinued
Additional measures installed: Additional measures installed:
 - C&D of shared sanitation using 1000ppm chlorine  - C&D of all patient rooms of half the department
 - Twice daily C&D of sanitation
 - Daily C&D of bedpan chairs
19/2 & 24/2 environmental cultures taken
 25/2 Use of only cardboard single use bedpans in toilet chairs
April 2016
October 2015 November 2015 December 2015
January 2016 February 2016 March 2016
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826 Case D - recurrence
826 Case A - initial episode
033
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826 Case D - initial episode
8051728_078
826 Case A - recurrence
078
7005405_078
826 Case E
10015222_078
126/078
